# Association between the Prevalence of cardiovascular risk factors and new use of testosterone

First published: 29/03/2018 Last updated: 01/04/2024



# Administrative details

#### **EU PAS number**

EUPAS23347

#### Study ID

29773

#### DARWIN EU® study

No

#### **Study countries**

United Kingdom

#### **Study status**

Finalised

## Research institutions and networks

## Institutions

Institute for Epidemiology, Statistics and Informatics

First published: 01/02/2024

Last updated: 01/02/2024



# Contact details

### Study institution contact

Carlos Martinez carlos.martinez@pharmaepi.com

Study contact

carlos.martinez@pharmaepi.com

Primary lead investigator Carlos Martinez

Primary lead investigator

# Study timelines

Date when funding contract was signed Actual: 13/04/2017

Study start date Planned: 01/04/2018

### Date of final study report

Planned: 31/05/2018 Actual: 14/06/2018

# Sources of funding

• Pharmaceutical company and other private sector

## More details on funding

Bayer AG

# Study protocol

BATES01 - 0.6 - Protocol\_Final\_geschwärzt.pdf(427.47 KB)

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

### **Study topic:**

Disease /health condition Human medicinal product

### Study type:

Non-interventional study

### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness Drug utilisation

### Data collection methods:

Secondary use of data

### Main study objective:

To investigate if testosterone is preferentially given to patients at higher risk profile for cardiovascular events.

# Study Design

### Non-interventional study design

Case-control

# Study drug and medical condition

# Study drug International non-proprietary name (INN) or common name

TESTOSTERONE

### Anatomical Therapeutic Chemical (ATC) code

(G03BA03) testosterone

testosterone

### Medical condition to be studied

Hypogonadism male

# Population studied

### Short description of the study population

All male individuals aged 18 years or older in the source population with a first testosterone use during the study period.

### Age groups

Adults (18 to < 46 years) Adults (46 to < 65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

### Estimated number of subjects

23000

# Study design details

#### Outcomes

Estimation of the association between cardiovascular risk factors and initiation of testosterone therapy

#### Data analysis plan

The study uses a case-control design. Cases will be ascertained using product and Read medical codes indicating testosterone use. Up to five controls will be drawn from the source population for each case, matched on year of birth, history of pathological hypogonadism (primary or secondary) and GP consultation ±30 days of the index day of the respective case. Descriptive statistics of demographic and baseline clinical characteristics on the index day will be presented for cases and matched controls, including lifestyle factors, pathological hypogonadism (primary or secondary), symptoms associated with hypogonadism, comorbidities, comedications and cardiovascular (CV) risk factors. Crude and adjusted odds ratios (OR) with 95% confidence intervals of the association between CV factors and initiation of testosterone therapy will be estimated using conditional logistic regression for matched case-control data. Results will be stratified by history of pathological hypogonadism.

## Documents

#### **Study results**

19547\_EU-PAS\_Abstract\_2019-05-13\_Redacted.pdf(128.24 KB)

#### **Study report**

19547\_study report\_EU PAS Register\_Redacted.pdf(635.93 KB)

## Data management

**ENCePP Seal** 

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

**Data source(s)** Clinical Practice Research Datalink

**Data sources (types)** Electronic healthcare records (EHR)

# Use of a Common Data Model (CDM)

**CDM mapping** 

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

### Check logical consistency

Unknown

# Data characterisation

### Data characterisation conducted

Unknown